GRAL
Grail·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GRAL
Grail, Inc.
A biotechnology company that uses liquid biopsy technology for early cancer detection
1525 O’Brien Drive, Menlo Park, California 94025
--
Grail, Inc., was incorporated in Delaware on September 11, 2015. The company is a healthcare company dedicated to saving lives and improving health by pioneering new technologies for early detection of cancer. The company has built a multidisciplinary organization of scientists, engineers and physicians that is leveraging the power of next generation sequencing (NGS), population-scale clinical research, and state-of-the-art computer science and data science to overcome one of medicine's greatest challenges. Using the company's platform technology, the company has developed a multi-cancer early detection blood test, which has demonstrated in clinical studies that more than 50 cancer types can be detected from a single blood draw and can highly accurately locate cancer signals.
Earnings Call
Q1/2025
Estimate EPS-3.8
Actual EPS-3.1
Estimate Revenue35.20M
Actual Revenue31.84M
GRAIL's Q1 2025: Navigating Contradictions in Cost Strategies, Partnerships, and Cash Flow
May 20,2025 02:26
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-3.56
Actual EPS-3.18
Estimate Revenue36.90M
Actual Revenue35.54M
GRAIL's 2025 Q2 Earnings Call: Unpacking Contradictions in Cash Burn, International Growth, and Regulatory Pathways
Aug 12,2025 07:26
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
GRAL has released its 2025 Q3 earnings. EPS was reported at -2.46, versus the expected -3.33, beating expectations. The chart below visualizes how GRAL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GRAL has released its 2025 Q3 earnings report, with revenue of 36.19M, reflecting a YoY change of 26.32%, and net profit of -88.98M, showing a YoY change of 29.21%. The Sankey diagram below clearly presents GRAL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
